ArticleJournal of proteomics2011
Protein signatures for survival and recurrence in metastatic melanoma.
Article in Journal of proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Integrating MALDI-MSI-Based Spatial Proteomics and Machine Learning to Predict Chemoradiotherapy Outcomes in Head and Neck Cancer.International journal of molecular sciences · 2025Article
- A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.International journal of molecular sciences · 2024Article
- Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.Dermatopathology (Basel, Switzerland) · 2024Review
- Imaging Mass Spectrometry for the Classification of Melanoma Based onInternational journal of molecular sciences · 2023Article
- Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.Journal of cutaneous pathology · 2021Article
- Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma.Cancers · 2021Article
- Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine.Chemical science · 2021Review
- Article
- Adamantinomatous craniopharyngioma: advances in proteomic research.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Review
- Article
- Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.Bioscience reports · 2019Article
- Investigating the Protein Signature of Adamantinomatous Craniopharyngioma Pediatric Brain Tumor Tissue: Towards the Comprehension of Its Aggressive Behavior.Disease markers · 2019Article
- Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management.Frontiers in medicine · 2018Review
- Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.Oncotarget · 2017Article
- Advances in MALDI imaging mass spectrometry of proteins in cardiac tissue, including the heart valve.Biochimica et biophysica acta. Proteins and proteomics · 2017Review
- Ultra-High Mass Resolution MALDI Imaging Mass Spectrometry of Proteins and Metabolites in a Mouse Model of Glioblastoma.Scientific reports · 2017Article
- Article
- MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues.Advances in cancer research · 2017Review
- A Proof of Concept to Bridge the Gap between Mass Spectrometry Imaging, Protein Identification and Relative Quantitation: MSI~LC-MS/MS-LF.Proteomes · 2016Article
- MDA-9 and GRP78 as potential diagnostic biomarkers for early detection of melanoma metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patients with melanoma metastatic to regional lymph nodes exhibit a range in tumor progression, survival, and treatment. Current approaches to stratify patients with this stage of disease predominantly involve clinical and histological methods. Molecular classification thus far has focused almost exclusively on genetic mutations. In this study, proteomic data from 69 melanoma lymph node metastases and 17 disease free lymph nodes acquired by histology-directed MALDI imaging mass spectrometry were used to classify tumor from control lymph node and to molecularly sub-classify patients with stage III disease. From these data, 12 survival associated protein signals and 3 recurrence associated signals in the acquired mass spectra were combined to generate a multiplex molecular signature to group patients into either poor or favorable groups for recurrence and survival. Proteins represented in the signature include cytochrome c, s100 A6, histone H4, and cleaved forms of thymosin β-4, thymosin β-10, and ubiquitin. In total over 40 protein signals from the tissue were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.